This is an open-label, randomized, 3x3 partial replicated crossover study to evaluate the pharmacokinectics and safety/tolerability. Within each period, randomized subjects will be 2 dosing regimens with a fixed dose combination of Fimasartan/Amlodipine and co-administration of Fimasartan and Amlodipine.